Imatinib Front-Line Therapy Is Safe and Effective in Patients With Chronic Myelogenous Leukemia With Pre-Existing Liver and/or Renal Dysfunction

BACKGROUND: Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous leukemia (CML). The safety and efficacy of imatinib in CML patients with pre-existing liver and/or renal dysfunction has not been analyzed. METHODS: The authors analyzed the outcome of 259 patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Tong, Wei-Gang, Kantarjian, Hagop, O'Brien, Susan, Faderl, Stefan, Ravandi, Farhad, Borthakur, Gautam, Shan, Jianqin, Pierce, Sherry, Rios, Mary Beth, Cortes, Jorge
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4314210/
https://ncbi.nlm.nih.gov/pubmed/20564631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25071
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares